# Comprehensive Policy Scenario Execution Plan
**HIVEC-CM HIV Epidemic Model - All Scenarios Analysis**

*Generated: October 26, 2025*

---

## Executive Summary

This document describes the comprehensive execution of all 9 policy scenarios for the Cameroon HIV epidemic model. The analysis runs from **1985-2030** (45 years) with a population of **50,000 agents** (1:238 scaling ratio).

### Scenarios Being Executed

| ID | Scenario Name | Description | Policy Question |
|----|---------------|-------------|-----------------|
| **S0** | Baseline | Status quo - current trends continue | What if we maintain 2022 performance levels? |
| **S1a** | Optimistic Funding | 20% budget increase via domestic mobilization | Impact of increased domestic investment? |
| **S1b** | Pessimistic Funding | **40% budget cut (2025)** | Impact of severe international funding withdrawal? |
| **S2a** | Intensified Testing | Scale-up index testing, self-testing, campaigns | How to close the "First 95" gap? |
| **S2b** | Key Populations | High-intensity KP package (FSW, MSM, PWID) | Impact of focused KP interventions? |
| **S2c** | eTME Achievement | Achieve <5% MTCT | Path to elimination of mother-to-child transmission? |
| **S2d** | Youth Focus | Improve cascade for ages 15-24 | Long-term impact of youth-focused interventions? |
| **S3a** | PSN Aspirational | Full PSN 2024-2030 implementation (95-95-95) | What if all strategic plan targets are met? |
| **S3b** | Geographic Priority | Concentrate resources in high-prevalence regions | Resource allocation strategy optimization? |

---

## Execution Configuration

### Simulation Parameters
```
Start Year:        1985
End Year:          2030
Years Simulated:   45
Population Size:   50,000 agents
Scaling Ratio:     1:238 (1 agent = 238 real people)
Real Population:   ~11.9 million
Time Step:         0.1 years (36.5 days)
Total Steps:       450
```

### Time-Varying Transmission (Calibrated)
```
Emergence Phase (1985-1990):  0.8x multiplier
Growth Phase (1990-2007):     6.0x multiplier
Decline Phase (2007-2030):    4.0x multiplier
```

### Validation Status
- ✅ Calibrated against 34 UNAIDS data points (1990-2023)
- ✅ MAE = 1.73% (target: <2.0%)
- ✅ All 4 trajectory criteria met (Growth, Peak, Decline, Accuracy)

---

## Scenario Details

### S0: Baseline (Status Quo)

**Configuration:**
- Testing rate: 29% (2022 levels)
- ART initiation: 85%
- ART retention (12m): 90%
- ART retention (24m): 85%
- Viral suppression: 75%
- Funding multiplier: 1.0

**Expected Outcomes:**
- Continued gradual decline in prevalence
- Modest progress toward 95-95-95
- Baseline for all comparisons

---

### S1a: Optimistic Funding (+20%)

**Configuration:**
- Funding multiplier: 1.20
- Testing rate: 38% (+30%)
- ART initiation: 92% (+8%)
- ART retention (12m): 95% (+5%)
- Viral suppression: 85% (+10%)
- Treatment interruptions: 2% (-60%)

**Expected Outcomes:**
- Accelerated epidemic control
- Faster approach to 95-95-95
- Reduced stockouts and service disruptions

---

### S1b: Pessimistic Funding (-40%) ⚠️

**Configuration:**
- Funding multiplier: 0.60 (40% cut starting 2025)
- Testing rate: 17% (-41% from baseline)
- ART initiation: 51% (-40%)
- ART retention (12m): 70% (-22%)
- ART retention (24m): 60% (-29%)
- Viral suppression: 50% (-33%)
- Treatment interruptions: 25% (5× increase)
- PrEP for KP: 2% (-80%)

**Key Population Crisis:**
- KP service availability: 30% (70% closure)
- KP testing reduction: 65%
- KP outreach workers: 25% (75% staff cuts)

**Expected Outcomes:**
- ⚠️ Epidemic reversal - sharp increase in new infections
- ⚠️ Rising AIDS deaths
- ⚠️ Collapse of KP programs
- ⚠️ Treatment cascade failures across all stages

---

### S2a: Intensified Testing

**Configuration:**
- Testing rate: 45% (+55% from baseline)
- Index testing: ENABLED
  - Partners per index: 1.5
  - Acceptance rate: 75%
  - Positivity: 40%
- Self-testing: ENABLED
  - Annual distribution: 500,000 kits
  - Uptake: 65%
  - Confirmatory testing: 80%
- Linkage to care: 90%

**Expected Outcomes:**
- Dramatic increase in diagnosis (First 95)
- Reduced undiagnosed infections
- Lower transmission from unaware individuals

---

### S2b: Key Populations Focus

**Configuration:**
- KP testing: 95% (quarterly testing)
- KP PrEP coverage: 95%
- KP condom use: 95%
- KP ART coverage: 95%
- KP viral suppression: 95%
- Peer navigator coverage: 80%
- Community mobilization effect: 30% risk reduction

**Target Groups:**
- Female Sex Workers (FSW)
- Men who have Sex with Men (MSM)
- People Who Inject Drugs (PWID)

**Expected Outcomes:**
- Substantial reduction in KP transmission
- Spillover benefits to general population
- Concentrated epidemic control

---

### S2c: eTME Achievement

**Configuration:**
- ANC coverage: 98%
- First trimester ANC: 75%
- PMTCT HIV testing: 98%
- PMTCT ART initiation: 98% (within 1 week)
- PMTCT viral suppression: 95%
- EID at 6 weeks: 98%
- EID at 18 months: 95%
- Target MTCT rate: <5%

**Expected Outcomes:**
- Dramatic reduction in pediatric HIV
- MTCT: 10.1% → <5%
- Path to eTME certification

---

### S2d: Youth & Adolescent Focus (15-24 years)

**Configuration:**
- Youth testing: 85%
- Youth self-test coverage: 60%
- Youth ART initiation: 90%
- Youth retention (12m): 88%
- Youth retention (24m): 85%
- Youth viral suppression: 85%
- Youth PrEP coverage: 40%
- Youth condom use: 70%

**Services:**
- Youth-friendly clinics
- Peer support groups
- mHealth (SMS) support
- Comprehensive sex education

**Expected Outcomes:**
- Reduced youth incidence
- Long-term epidemic control
- Generational HIV elimination

---

### S3a: PSN 2024-2030 Aspirational (95-95-95)

**Configuration:**
- First 95 (diagnosis): 95%
- Second 95 (on ART): 95%
- Third 95 (suppressed): 95%
- MTCT rate: <5%
- PrEP coverage KP: 95%
- PrEP coverage youth: 40%
- VMMC coverage: 80%
- Testing coverage: 60% annual
- Treatment interruptions: 1%

**Expected Outcomes:**
- Full PSN strategic plan achievement
- Epidemic control by 2030
- Near-elimination scenario

---

### S3b: Geographic Prioritization

**Strategy Options:**
1. High-prevalence regions (Sud, Est, Centre)
2. Urban centers (Douala, Yaoundé)
3. Balanced approach

**Configuration (High-Prevalence Focus):**
- Priority testing boost: +30%
- Priority linkage boost: +30%
- Priority retention boost: +25%
- Priority prevention boost: +35%
- Non-priority service level: 85% of baseline

**Expected Outcomes:**
- Efficient resource allocation
- Regional epidemic heterogeneity
- Optimization insights

---

## Expected Outputs

### Per-Scenario Outputs

Each scenario generates:

1. **simulation_results.csv**
   - Annual time series (1985-2030)
   - Population dynamics
   - HIV prevalence trajectory
   - New infections, AIDS deaths, births
   - Treatment cascade metrics
   - ART coverage, viral suppression

2. **metadata.json**
   - Scenario configuration
   - All parameter values
   - Execution time
   - Model version
   - Timestamp

3. **detailed_results/** (if enabled)
   - Age-sex stratified prevalence
   - Regional breakdowns
   - Treatment cascade transitions
   - Testing modality data
   - Co-infection tracking

### Aggregate Outputs

**execution_summary.json**
- All scenario results compiled
- Comparative metrics
- Execution statistics
- Success/failure status

---

## Comparative Analysis Metrics

### Primary Indicators
1. **HIV Prevalence (2030)**
   - Overall adult prevalence (15-49)
   - Age-sex stratified
   - Regional variations

2. **New Infections (Annual)**
   - 2025 baseline year
   - 2030 endpoint
   - Cumulative 2025-2030

3. **AIDS Deaths (Annual)**
   - 2025 baseline
   - 2030 endpoint
   - Cumulative 2025-2030

4. **Treatment Cascade (2030)**
   - First 95: % diagnosed
   - Second 95: % on ART
   - Third 95: % virally suppressed

### Secondary Indicators
5. **MTCT Rate** (Scenario 2c comparison)
6. **KP Outcomes** (Scenario 2b comparison)
7. **Youth Prevalence** (Scenario 2d comparison)
8. **Cost-Effectiveness** (per infection averted)

---

## Analysis Plan

### Phase 1: Individual Scenario Assessment
- Review each scenario's trajectory
- Validate against baseline
- Identify key inflection points
- Document unexpected behaviors

### Phase 2: Comparative Analysis
- Create comparison tables
- Generate comparative plots:
  - Prevalence trajectories (all scenarios)
  - New infections comparison
  - AIDS deaths comparison
  - Treatment cascade comparison (2030)
  - Cost-benefit analysis

### Phase 3: Policy Recommendations
- Rank scenarios by effectiveness
- Assess feasibility vs impact
- Identify optimal intervention packages
- Resource allocation recommendations

---

## Technical Specifications

### Computational Requirements
```
Per Scenario:
  - Population: 50,000 agents
  - Steps: 450 (45 years × 10 steps/year)
  - Agent-years: 2.25 million
  - Estimated time: 8-12 minutes
  
Total (9 scenarios):
  - Agent-years: 20.25 million
  - Estimated time: 72-108 minutes (1.2-1.8 hours)
  - Memory: ~8-12 GB peak
  - Storage: ~500 MB total output
```

### Model Version
```
HIVEC-CM Version: v7 (Time-Varying Optimized)
Calibration: 4.0x decline multiplier
Validation: MAE=1.73% (1990-2023)
Python: 3.9+
Dependencies: See requirements.txt
```

---

## Execution Timeline

### Scenario Execution Order
```
1. S0_baseline              (12 min)  ✓ Reference
2. S1a_optimistic_funding   (12 min)  ✓ Positive scenario
3. S1b_pessimistic_funding  (10 min)  ⚠️ Crisis scenario
4. S2a_intensified_testing  (13 min)  ✓ Testing focus
5. S2b_key_populations      (12 min)  ✓ KP focus
6. S2c_emtct                (12 min)  ✓ PMTCT focus
7. S2d_youth_focus          (12 min)  ✓ Youth focus
8. S3a_psn_aspirational     (13 min)  ✓ Optimal scenario
9. S3b_geographic           (12 min)  ✓ Geographic strategy

Total Estimated: ~1.8 hours
```

### Post-Processing
- Comparative visualization: 30 min
- Statistical analysis: 20 min
- Report generation: 40 min
- **Total project time: ~3 hours**

---

## Key Comparisons of Interest

### 1. Funding Impact (S0 vs S1a vs S1b)
**Question:** How sensitive is the epidemic to funding changes?

Compare:
- S0 (Baseline) vs S1a (+20%) vs S1b (-40%)
- Prevalence trajectories 2025-2030
- Cumulative infections/deaths averted or excess

### 2. Testing Strategies (S0 vs S2a)
**Question:** Can enhanced testing close the First 95 gap?

Compare:
- Diagnosis rates
- Time to diagnosis
- Undiagnosed PLHIV

### 3. Population-Specific Interventions (S2b, S2c, S2d)
**Question:** Which target population interventions have greatest impact?

Compare:
- KP outcomes (S2b)
- Pediatric HIV (S2c)
- Youth incidence (S2d)

### 4. Aspirational vs Realistic (S0 vs S3a)
**Question:** Gap between current trajectory and full PSN achievement?

Compare:
- 95-95-95 achievement rates
- Prevalence reduction
- Infections/deaths averted

### 5. Geographic Strategy (S3b variants)
**Question:** Optimal resource allocation across regions?

Compare:
- Regional prevalence patterns
- Equity vs efficiency tradeoffs
- National vs regional optimization

---

## Risk Assessment

### Scenario S1b (Pessimistic Funding) - HIGH RISK ⚠️

**Warning Indicators:**
- 40% funding cut = catastrophic impact
- Treatment cascade collapse (51% ART initiation)
- KP programs nearly eliminated (80% PrEP reduction)
- Expected epidemic reversal

**Mitigation Strategies:**
- Advocate for sustained funding
- Diversify funding sources
- Maintain core services at all costs
- Prioritize most efficient interventions

---

## Validation & Quality Control

### Pre-Execution Checks
- ✅ Calibrated model (MAE=1.73%)
- ✅ Time-varying transmission validated
- ✅ All scenario definitions complete
- ✅ Parameter ranges realistic
- ✅ Output directories created

### During Execution
- Monitor for crashes/errors
- Check intermediate results
- Validate trajectory shapes
- Track execution time

### Post-Execution
- Verify all scenarios completed
- Check result file sizes
- Validate prevalence ranges
- Review convergence
- Statistical outlier detection

---

## Next Steps After Execution

### Immediate (Day 1)
1. ✅ Verify all scenarios completed successfully
2. Generate comparative prevalence plot (9 trajectories)
3. Create summary statistics table
4. Identify any anomalies or unexpected results

### Short-term (Week 1)
1. Detailed comparative analysis
2. Policy brief document
3. Presentation slides for stakeholders
4. Scientific manuscript draft

### Medium-term (Month 1)
1. Sensitivity analysis on key parameters
2. Monte Carlo robustness testing (10 runs per scenario)
3. Cost-effectiveness analysis
4. Regional sub-analysis

---

## Output Directory Structure

```
results/policy_scenarios_2025/
├── execution_summary.json
├── S0_baseline/
│   ├── simulation_results.csv
│   ├── metadata.json
│   └── plots/ (if generated)
├── S1a_optimistic_funding/
│   ├── simulation_results.csv
│   └── metadata.json
├── S1b_pessimistic_funding/
│   ├── simulation_results.csv
│   └── metadata.json
├── S2a_intensified_testing/
│   ├── simulation_results.csv
│   └── metadata.json
├── S2b_key_populations/
│   ├── simulation_results.csv
│   └── metadata.json
├── S2c_emtct/
│   ├── simulation_results.csv
│   └── metadata.json
├── S2d_youth_focus/
│   ├── simulation_results.csv
│   └── metadata.json
├── S3a_psn_aspirational/
│   ├── simulation_results.csv
│   └── metadata.json
└── S3b_geographic/
    ├── simulation_results.csv
    └── metadata.json
```

---

## Contact & Support

**Model:** HIVEC-CM (HIV Epidemic Cameroon Model)  
**Version:** 7.0 (Time-Varying Calibrated)  
**Execution Date:** October 26, 2025  
**Analyst:** Blake Nkemngu  
**Institution:** Cameroon HIV Research Team

---

## References

1. PSN 2024-2030 Strategic Plan, Cameroon Ministry of Health
2. UNAIDS Cameroon Country Data (2023)
3. CAMPHIA Survey Results (2017-2018)
4. HIVEC-CM Model Documentation (docs/)
5. Time-Varying Calibration Report (TIME_VARYING_FINAL_REPORT.md)

---

**Status:** ⏳ EXECUTION IN PROGRESS  
**Expected Completion:** ~1.8 hours from start  
**Next Update:** Post-execution summary
